Autoantibody signatures as biomarkers to distinguish prostate cancer from benign prostatic hyperplasia in patients with increased serum prostate specific antigen.
about
The Present and Future of Biomarkers in Prostate Cancer: Proteomics, Genomics, and Immunology AdvancementsDiagnosis of prostate cancer via nanotechnological approachNovel prostate cancer biomarkers derived from autoantibody signatures.Serum Autoantibodies in Chronic Prostate Inflammation in Prostate Cancer Patients.Antibody profiling with protein antigen microarrays in early stage cancer.Evaluation and characterization of anti-RalA autoantibody as a potential serum biomarker in human prostate cancer.Autoantibodies against oncogenic ERG protein in prostate cancer: potential use in diagnosis and prognosis in a panel with C-MYC, AMACR and HERV-K Gag.RNA-binding proteins as molecular links between cancer and neurodegeneration.Immunoseroproteomic Profiling in African American Men with Prostate Cancer: Evidence for an Autoantibody Response to Glycolysis and Plasminogen-Associated Proteins.The significance of autoantibodies to DFS70/LEDGFp75 in health and disease: integrating basic science with clinical understanding.Using Serological Proteome Analysis to Identify Serum Anti-Nucleophosmin 1 Autoantibody as a Potential Biomarker in European-American and African-American Patients With Prostate Cancer.The Clinical Relevance of Anti-DFS70 Autoantibodies.Autoantibodies against TYMS and PDLIM1 proteins detected as circulatory signatures in Indian breast cancer patients.A highly sensitive capillary electrophoresis immunoassay strategy based on dual-labeled gold nanoparticles enhancing chemiluminescence for the detection of prostate-specific antigen.Molecular analyses of prostate tumors for diagnosis of malignancy on fine-needle aspiration biopsies.Longitudinal autoantibody responses against tumor-associated antigens decrease in breast cancer patients according to treatment modality.
P2860
Q26750672-6F041B9F-D4D8-4D4F-842A-65551FB31B92Q26777322-A904A6DC-C196-4451-A219-AC8FD4170135Q35555399-4E315061-5F96-481D-86D2-9874E774477BQ35919544-EBEF3F7B-1EC1-48D0-9964-BB952B60DA94Q36682206-C6E30378-134E-4910-8E4C-081605ACECDEQ37536632-FCCE7245-538F-41BB-BF7B-DB6C267BCA05Q37635618-52D89702-383C-4FDA-8179-C16CB516A3C4Q38251313-779A373C-304C-44A7-BE7B-CC2812499A64Q38386585-57D6B856-613E-41D5-9B21-F3B941DCCF3CQ38531451-43E26C0A-2F2B-439F-A2E8-AA4B7BFA937CQ38758065-B345D1FA-565B-4EAC-AE7E-A935322B5A88Q38879029-B56C7027-43DD-41AA-9721-25A1316010F3Q39858992-2FB4CB36-65B8-4145-A71F-07508A704CA3Q46388187-E19F40D2-183E-428A-98F2-29CB5D083F9CQ47106447-FF0058CF-BA4F-4635-844F-E527CE14AC92Q49419816-D96FC81A-5534-46E3-8380-D76960C4A9FB
P2860
Autoantibody signatures as biomarkers to distinguish prostate cancer from benign prostatic hyperplasia in patients with increased serum prostate specific antigen.
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
2011年论文
@zh
2011年论文
@zh-cn
name
Autoantibody signatures as bio ...... rum prostate specific antigen.
@en
type
label
Autoantibody signatures as bio ...... rum prostate specific antigen.
@en
prefLabel
Autoantibody signatures as bio ...... rum prostate specific antigen.
@en
P2093
P2860
P1433
P1476
Autoantibody signatures as bio ...... rum prostate specific antigen.
@en
P2093
Brian C-S Liu
Daniel A DiJohnson
Dennis J O'Rourke
James C Nelson
Jerome P Richie
Michael P O'Leary
Robert J Caiazzo
P2860
P304
P356
10.1016/J.CCA.2011.11.027
P577
2011-11-29T00:00:00Z